HC Wainwright Comments on Cytokinetics Q3 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – HC Wainwright issued their Q3 2026 earnings estimates for shares of Cytokinetics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($2.03) for the quarter. HC Wainwright has a “Buy” rating and a $136.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ FY2026 earnings at ($7.12) EPS, FY2027 earnings at ($5.12) EPS and FY2028 earnings at ($1.67) EPS.

A number of other brokerages have also commented on CYTK. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. JPMorgan Chase & Co. lifted their target price on Cytokinetics from $70.00 to $74.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Citizens Jmp upped their price target on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Barclays started coverage on shares of Cytokinetics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price objective on the stock. Finally, Morgan Stanley set a $90.00 target price on shares of Cytokinetics in a report on Thursday, January 8th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and an average price target of $88.83.

Cytokinetics Trading Down 0.7%

CYTK opened at $62.22 on Friday. The stock has a market capitalization of $7.61 billion, a P/E ratio of -9.53 and a beta of 0.54. Cytokinetics has a 12 month low of $29.31 and a 12 month high of $70.98. The firm’s fifty day simple moving average is $64.20 and its 200 day simple moving average is $58.75.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. During the same period in the previous year, the business earned ($1.26) EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis.

Institutional Investors Weigh In On Cytokinetics

Hedge funds have recently bought and sold shares of the company. Woodline Partners LP increased its position in Cytokinetics by 676.1% during the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after buying an additional 1,435,422 shares during the last quarter. Norges Bank bought a new position in shares of Cytokinetics during the 2nd quarter worth approximately $39,122,000. Deep Track Capital LP boosted its stake in shares of Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after acquiring an additional 650,000 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Cytokinetics by 151,987.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after acquiring an additional 565,393 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new stake in Cytokinetics in the 2nd quarter valued at $18,328,000.

Insiders Place Their Bets

In other Cytokinetics news, Director Edward M. Md Kaye sold 28,064 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $66.72, for a total value of $1,872,430.08. Following the completion of the sale, the director owned 9,977 shares in the company, valued at $665,665.44. This trade represents a 73.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Andrew Callos sold 52,486 shares of Cytokinetics stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70. Following the completion of the transaction, the executive vice president directly owned 50,660 shares of the company’s stock, valued at approximately $3,341,027. This trade represents a 50.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 151,385 shares of company stock valued at $9,817,158 in the last ninety days. 2.70% of the stock is currently owned by insiders.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.